A desperate workaround
A woman sits at her computer, heart racing. She fills out an online pharmacy form. When the field for 'Gender' appears, she hesitates. She clicks 'Male.' She is not a man, but she needs the gel. She needs the testosterone to stop the brain fog, the bone density loss, and the crushing fatigue that makes waking up feel like a mountain climb. She is part of a growing, quiet movement of women using male identities to bypass a broken healthcare system.
This isn't a case of identity theft or simple fraud. It is a symptom of a much deeper clinical failure. In parts of the UK, particularly across Wales and parts of England, menopausal women are finding that the easiest way to access essential hormone replacement therapy (HRT) is to pretend they are men. They are navigating an underground market of medical desperation, driven by a systemic inability to provide gender-specific care to women in midlife.
The mechanics are simple and bleak. Testosterone, often used in low doses for women to combat libido loss and cognitive decline, is frequently in short supply. When traditional prescribing pathways through the NHS fail due to stock shortages or overly restrictive clinical guidelines, women turn to online pharmacies. These digital providers often have faster turnover or different stock priorities. But the gates are closed to women for many types of testosterone formulations, so women simply change their profile to bypass the gatekeepers.
The shadow of medical gaslighting
For decades, women’s health has existed in the periphery of medical research. While menopausal symptoms are often dismissed as "just aging" or "emotional instability," the physiological reality is a massive shift in endocrine function. The drop in estrogen is the catalyst, but the subsequent decline in androgens—like testosterone—can be devastating for a woman's quality of life. Yet, when women seek help for these symptoms, they frequently encounter gaslighting. They are told their symptoms are psychological, or that the risks of hormone therapy outweigh the benefits, regardless of the patient's specific history.
This skepticism creates a barrier to entry. Even when a woman has a legitimate clinical need, the friction of obtaining a prescription can be immense. Doctors may be hesitant to prescribe due to outdated safety profiles or simply because they lack specialized training in midlife endocrinology. When the professional encounter is met with doubt, the patient loses faith in the institution. When the institution fails to provide the medication, the patient seeks the medication elsewhere.
This is not just a gap in empathy; it is a gap in science. For much of the 20th century, clinical trials focused heavily on male subjects. The hormonal fluctuations of the female lifecycle were treated as a secondary variable or ignored entirely. This historical neglect means that current prescribing protocols are often built on a foundation of incomplete data, leaving women to navigate a medical landscape that was never designed with them in mind.
Supply chain fragility and gendered shortages
The current crisis is exacerbated by a volatile pharmaceutical supply chain. Recently, the UK has faced significant shortages of various HRT components. When shortages hit, pharmacies and health boards often implement triage systems. In these scenarios, resources are diverted to where they are deemed most "medically necessary" or where the demand is most documented. Historically, testosterone has been viewed through the lens of male sexual health. Consequently, when stock runs low, the existing infrastructure often prioritizes the male demographic, leaving women struggling to find even small doses of the hormone.
This creates a hierarchy of need that privileges men. A man seeking testosterone for hypogonadism is often met with a standardized, robust clinical pathway. A woman seeking the same hormone to maintain bone density or metabolic health faces a labyrinth of gatekeeping and scarcity. The result is a systemic inequity where the most vulnerable patients are pushed toward unregulated or illicit channels just to maintain basic physiological stability.
Advocates for menopausal health argue that this is a failure of pharmaceutical stock management. If the supply chain does not account for the specific, predictable needs of the female population during menopause, the system will remain broken. By failing to secure reliable, gender-specific hormone supplies, the NHS is effectively forcing women into the shadows of the healthcare market.
The cost of policing instead of providing
There is a growing conversation about how we respond to these women. The instinct of many regulatory bodies is to focus on "policing"—to crack down on the online pharmacies and the women who circumvent the rules. The conversation centers on the ethics of misrepresenting one's gender to obtain medication. While this focus on "deception" is loud, it is largely a distraction from the underlying pathology of the healthcare system.
By framing this as a matter of rule-breaking, the conversation avoids the real question: Why is the medication unavailable? Why is the prescribing pathway so hostile? Why is a woman forced to lie about her identity to receive a treatment that a doctor would otherwise approve? The emphasis on policing women for their survival strategies treats the symptom rather than the disease. It places the moral burden on the patient rather than the provider.
If the medical community spent half as much energy reforming prescribing pathways and stabilizing hormone stocks as it does monitoring for "impersonation," the problem would likely vanish. The focus must shift from the act of deception to the act of deprivation. We are seeing a collapse of female health autonomy because the system makes it too difficult and too expensive to be a woman in menopause.
Toward a new model of care
Reforming this requires a shift in how we value female aging. It means moving away from a one-size-fits-all hormonal model and toward a nuanced, gender-informed approach. This involves better integration of endocrine health into primary care and a commitment to ensuring that the supply chains for women's hormones are treated with the same urgency as those for men's health.
We must also address the invisible patient. The woman who manages her symptoms in secret, who hides her struggle to avoid being judged or labeled, is a testament to a system that has failed its most consistent user base. The goal should not be to catch the woman pretending to be a man; the goal should be to ensure that no woman ever feels she has to do so to survive her own biology.
